Hemostemix Inc. (HEM.V) TSXV

0.10

+0.005(+5.26%)

Updated at September 26 03:38PM

Currency In CAD

Hemostemix Inc.

Address

707-7th Avenue SW

Calgary, AB T2P 3H6

Canada

Phone

905-580-4170

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

First IPO Date

November 28, 2014

Key Executives

NameTitlePayYear Born
Mr. Thomas A. Smeenk B.A., BA HonsCo-Founder, President, Chief Executive Officer & Director308,0001962
Ms. Christina Wu CPAInterim Chief Financial Officer65,381N/A
Dr. Fraser C. Henderson Sr., M.D.Chief Medical Officer0N/A
Mr. Peter PavlinVice President of Operations0N/A

Description

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.